239 related articles for article (PubMed ID: 34100301)
1. Current landscape of immunotherapy trials in locally advanced and high-risk head and neck cancer.
Park R; Park JC
Immunotherapy; 2021 Aug; 13(11):931-940. PubMed ID: 34100301
[TBL] [Abstract][Full Text] [Related]
2. Advancements in neoadjuvant immune checkpoint inhibitor therapy for locally advanced head and neck squamous Carcinoma: A narrative review.
Li J; Luo Z; Jiang S; Li J
Int Immunopharmacol; 2024 Jun; 134():112200. PubMed ID: 38744175
[TBL] [Abstract][Full Text] [Related]
3. Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy.
Vathiotis IA; Johnson JM; Argiris A
Cancer Treat Rev; 2021 Jun; 97():102192. PubMed ID: 33819755
[TBL] [Abstract][Full Text] [Related]
4. Evolving role of novel radiosensitizers and immune checkpoint inhibitors in (chemo)radiotherapy of locally advanced head and neck squamous cell carcinoma.
Ngamphaiboon N; Chairoungdua A; Dajsakdipon T; Jiarpinitnun C
Oral Oncol; 2023 Oct; 145():106520. PubMed ID: 37467684
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Approaches With Immune Checkpoint Inhibitors in Head and Neck Cancers and the Role of PD-L1 as a Biomarker.
Oualla K; Castelo Branco L; Nouiyakh L; Amaadour L; Benbrahim Z; Arifi S; Mellas N
Cancer Control; 2021; 28():10732748211004878. PubMed ID: 33827280
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus.
Wang H; Zhao Q; Zhang Y; Zhang Q; Zheng Z; Liu S; Liu Z; Meng L; Xin Y; Jiang X
Front Immunol; 2021; 12():652054. PubMed ID: 34305889
[TBL] [Abstract][Full Text] [Related]
7. The current advances and future directions of PD-1/PD-L1 blockade in head and neck squamous cell carcinoma (HNSCC) in the era of immunotherapy.
Chen Y; Ding X; Bai X; Zhou Z; Liu Y; Zhang X; Yu J; Hu M
Int Immunopharmacol; 2023 Jul; 120():110329. PubMed ID: 37207445
[TBL] [Abstract][Full Text] [Related]
8. Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma.
Xu X; Li R; Zhang L; Zhu G; Ren D; Wu L; Gong X
Diagn Pathol; 2021 Nov; 16(1):110. PubMed ID: 34823553
[TBL] [Abstract][Full Text] [Related]
9. Current and Future Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma.
Park JC; Krishnakumar HN; Saladi SV
Curr Oncol; 2022 Jun; 29(6):4185-4198. PubMed ID: 35735443
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
Leidner R; Crittenden M; Young K; Xiao H; Wu Y; Couey MA; Patel AA; Cheng AC; Watters AL; Bifulco C; Morris G; Rushforth L; Nemeth S; Urba WJ; Gough M; Bell RB
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963014
[TBL] [Abstract][Full Text] [Related]
11. Revisiting the concept of neoadjuvant and induction therapy in head and neck cancer with the advent of immunotherapy.
Smussi D; Mattavelli D; Paderno A; Gurizzan C; Lorini L; Romani C; Bignotti E; Grammatica A; Ravanelli M; Bossi P
Cancer Treat Rev; 2023 Dec; 121():102644. PubMed ID: 37862833
[TBL] [Abstract][Full Text] [Related]
12. The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer.
Qiao XW; Jiang J; Pang X; Huang MC; Tang YJ; Liang XH; Tang YL
Front Immunol; 2020; 11():1721. PubMed ID: 33072064
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers and 3D models predicting response to immune checkpoint blockade in head and neck cancer (Review).
Affolter A; Kern J; Bieback K; Scherl C; Rotter N; Lammert A
Int J Oncol; 2022 Jul; 61(1):. PubMed ID: 35642667
[TBL] [Abstract][Full Text] [Related]
14. Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches.
Vathiotis IA; Johnson JM; Luginbuhl A; Cognetti D; Curry J; Argiris A
Cancer Treat Rev; 2022 Sep; 109():102437. PubMed ID: 35868194
[TBL] [Abstract][Full Text] [Related]
15. Introducing Checkpoint Inhibitors Into the Curative Setting of Head and Neck Cancers: Lessons Learned, Future Considerations.
Nenclares P; Rullan A; Tam K; Dunn LA; St John M; Harrington KJ
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-16. PubMed ID: 35522916
[TBL] [Abstract][Full Text] [Related]
16. Emerging immune checkpoint inhibitors for the treatment of head and neck cancers.
Green SE; McCusker MG; Mehra R
Expert Opin Emerg Drugs; 2020 Dec; 25(4):501-514. PubMed ID: 33196319
[No Abstract] [Full Text] [Related]
17. Immunotherapy for head and neck squamous cell carcinoma: current status and perspectives.
Daste A; Larroquette M; Gibson N; Lasserre M; Domblides C
Immunotherapy; 2024 Feb; 16(3):187-197. PubMed ID: 38126161
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant immunotherapy in head and neck cancer: Rationale, current evidence and future perspective.
Cabezas-Camarero S; Pérez-Segura P
Crit Rev Oncol Hematol; 2022 Jan; 169():103569. PubMed ID: 34890800
[TBL] [Abstract][Full Text] [Related]
19. A systematic review of neoadjuvant and definitive immunotherapy in locally advanced head and neck squamous cell carcinoma.
Nindra U; Hurwitz J; Forstner D; Chin V; Gallagher R; Liu J
Cancer Med; 2023 May; 12(10):11234-11247. PubMed ID: 36934434
[TBL] [Abstract][Full Text] [Related]
20. Combination of radiation therapy-immunotherapy for head and neck cancers: Promises kept?
Huguet F; Durand B; Atallah S; Prébet C; Richard S; Baujat B
Cancer Radiother; 2021 Dec; 25(8):811-815. PubMed ID: 34711485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
